Zegfrovy Sunvozertinib, a fairly new therapeutic agent, is generating significant buzz within the oncology community. Its mechanism of action mainly involves targeted inhibition of epidermal growth factor receptor (EGFR) protein activity, showing potential in treating various cancerous forms. Early clinical studies have demonstrated encouraging dat